Literature DB >> 16490950

Secondary prevention of stroke in patients with atrial fibrillation: factors influencing the prescription of oral anticoagulation at discharge.

Dominique Deplanque1, Didier Leys, Lucilla Parnetti, Reinhold Schmidt, Jose Ferro, Jacques de Reuck, Jean-Louis Mas, Virgilio Gallai.   

Abstract

BACKGROUND: Oral anticoagulation (OAC) is the only treatment that has shown a significant benefit to reduce the risk of recurrence in patients with ischemic stroke and nonvalvular atrial fibrillation (NVAF). However, OAC is still underused, even at discharge from neurological centers. The objective of this study was to identify the reasons underlying the prescription of OAC at discharge after an ischemic stroke in patients with NVAF.
METHODS: We investigated the reasons why ischemic stroke patients with NVAF were not treated with OAC at discharge from 40 centers located in 5 European countries (Austria, Belgium, France, Italy, and Portugal).
RESULTS: Of 320 ischemic stroke survivors at discharge, 186 (58.1%) received OAC, while 260 (81.3%) patients were theoretically eligible according to guidelines and the absence of contraindications. There were significant differences between countries and the logistic regression analysis found being already under OAC before stroke, having no leukoaraiosis, having no potential contraindication, being younger than 75 years, being married and suffering from angina pectoris as independent predictors of being discharged under OAC.
CONCLUSION: This study suggests that besides patient-related factors, the prescription of OAC is also significantly influenced by the social environment and national practices. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16490950     DOI: 10.1159/000091546

Source DB:  PubMed          Journal:  Cerebrovasc Dis        ISSN: 1015-9770            Impact factor:   2.762


  9 in total

1.  Two-dimensional versus three-dimensional transesophageal echocardiography in percutaneous left atrial appendage occlusion.

Authors:  Witold Streb; Katarzyna Mitręga; Tomasz Podolecki; Magdalena Szymała; Anna Leopold-Jadczyk; Tomasz Kukulski; Zbigniew Kalarus
Journal:  Cardiol J       Date:  2018-03-07       Impact factor: 2.737

Review 2.  Nucleic Acid Therapies for Ischemic Stroke.

Authors:  Nils Henninger; Yunis Mayasi
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

3.  Stroke due to atrial fibrillation and the attitude to prescribing anticoagulant prevention in Italy. A prospective study of a consecutive stroke population admitted to a comprehensive stroke unit.

Authors:  C Gandolfo; M Balestrino; A Burrone; M Del Sette; C Finocchi
Journal:  J Neurol       Date:  2008-06-20       Impact factor: 4.849

4.  Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use.

Authors:  Thomas Wilke; Antje Groth; Matthias Pfannkuche; Oliver Harks; Andreas Fuchs; Ulf Maywald; Bernd Krabbe
Journal:  J Thromb Thrombolysis       Date:  2015-07       Impact factor: 2.300

Review 5.  Stroke prevention: modifying risk factors.

Authors:  José Rafael Romero; Jane Morris; Aleksandra Pikula
Journal:  Ther Adv Cardiovasc Dis       Date:  2008-08

Review 6.  Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation.

Authors:  A John Camm; Fausto J Pinto; Graeme J Hankey; Felicita Andreotti; F D Richard Hobbs
Journal:  Europace       Date:  2015-07       Impact factor: 5.214

7.  Factors Influencing Oral Anticoagulant Prescribing Practices for Atrial Fibrillation.

Authors:  Lester Y Leung; Mark McAllister; Magdy Selim; Marc Fisher
Journal:  J Stroke       Date:  2017-05-02       Impact factor: 6.967

8.  Influence of lipid profiles on the risk of hemorrhagic transformation after ischemic stroke: systematic review.

Authors:  Katiuscia Nardi; Didier Leys; Paolo Eusebi; Charlotte Cordonnier; Sophie Gautier; Hilde Hénon; Régis Bordet
Journal:  Cerebrovasc Dis Extra       Date:  2011-12-29

9.  Adherence to Guidelines for Antithrombotic Therapy in Patients with Atrial Fibrillation According to CHADS2 Score before and after Stroke: A Multicenter Observational Study from Korea.

Authors:  Wook Joo Kim; Jong Moo Park; Kyusik Kang; Yong Jin Cho; Keun Sik Hong; Soo Joo Lee; Youngchai Ko; Kyung Bok Lee; Tai Hwan Park; Jun Lee; Jae Kwan Cha; Dae Hyun Kim; Kyung Ho Yu; Byung Chul Lee; Mi Sun Oh; Juneyoung Lee; Jisung Lee; Myung Suk Jang; Moon Ku Han; Hee Joon Bae
Journal:  J Clin Neurol       Date:  2015-11-04       Impact factor: 3.077

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.